USA flag logo/image

An Official Website of the United States Government

Development of a Vaccine for the Treatment and/or Prevention of Cancer

Award Information

Agency:
Department of Defense
Branch:
Army
Award ID:
52795
Program Year/Program:
2001 / SBIR
Agency Tracking Number:
A002-2147
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
MATTEK CORPORATION
200 HOMER AVE ASHLAND, MA -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2001
Title: Development of a Vaccine for the Treatment and/or Prevention of Cancer
Agency / Branch: DOD / ARMY
Contract: DAMD17-01-C-0012
Award Amount: $70,000.00
 

Abstract:

Prostate cancer is the most common non-skin malignancy in the United States. With the exception of lung cancer, it is the leading cause of death in men in the country. By age 80, the risk of developing prostate cancer is estimated to be 1 in 7. Despiteincreased public awareness, regular check-ups, and improved therapeutic interventions, greater than 31,000 American men will die from prostate cancer during calendar year 2000. The current proposal seeks to develop a new form of immunotherapy usingdendritic cell based DNA vaccines to combat this serious disease. During Phase I, in vitro studies will be performed to lay the groundwork for an improved DNA vaccine against prostate cancer. This vaccine will result in increased antigen presentation byutilizing dendritic cells (DC) to administer a combination of prostate cancer, immuno-stimulatory cytokines, and chemokine receptor genes. The transformed DC will be more efficient at presenting antigen to T cells resulting in enhanced killing of prostatecancer tumor cells by cytolytic T-lymphocytes. The proposed vaccine offers a therapy for advanced prostate cancer for which currently no cure is available. The proof of concept in vitro studies in this proposal will form the basis for Phase I and PhaseII human clinical trials. In addition to providing a means of combating this serious, often-fatal disease, the proposed vaccine strategy will find applications in other fields of cancer, including breast and ovarian cancer, as well as in fightinginfectious diseases such as HIV/AIDS.

Principal Investigator:

Seyoum Ayehunie
Senior Cell Biologist
5088816771
info@mattek.com

Business Contact:

Mitchell Klausner
VP Scientific Affairs
5088816771
mklausner@mattek.com
Small Business Information at Submission:

MATTEK CORP.
200 Homer Ave Ashland, MA 01721

EIN/Tax ID: 042877744
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No